Clinical Trials Browser

Unknown × Interventional × Nivolumab × Clear all

NCT06566391 2024-08-22

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

Phase 2 Unknown

Melanoma

NCT04062656 2024-03-12

IMAGINE

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT06304597 2024-03-12

PREDICT

Phase 1 Unknown

Gastrointestinal

Locally Advanced Rectal Carcinoma

NCT05178043 2024-02-22

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03146650 2024-01-18

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Phase 2 Unknown

25 enrolled 14 charts

Salivary Gland Neoplasms

NCT06204614 2024-01-12

Drug Screening Using IMD in Bladder Cancer

Phase EARLY_PHASE1 Unknown

Muscle Invasive Bladder Urothelial Carcinoma

NCT05859477 2024-01-02

NIVOFGFR2

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT05150236 2023-12-15

ANZUP2001

Phase 2 Unknown

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT03638375 2023-12-12

ACTME

Phase 1/2 Unknown

Melanoma, Drug-Related Side Effects and Adverse Reactions

NCT05088889 2023-11-28

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Phase 1 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT02977052 2023-11-15

OpACIN-neo

Phase 2 Unknown

Melanoma

NCT03097939 2023-10-11

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT06031597 2023-09-13

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT04741438 2023-08-30

RAR-Immune

Phase 3 Unknown

Sarcoma

NCT05767684 2023-08-25

Neoantigen Derived DCs as Cancer Treatment

Phase 1 Unknown

Neoplasms

NCT03313544 2023-04-21

Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

Phase 4 Unknown

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT05821751 2023-04-20

PRINCESS

Phase NA Unknown

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Neoplasm Metastasis

NCT04981899 2023-04-12

NICE-40

Phase 1/2 Unknown

Hodgkin Disease

NCT03528408 2023-04-11

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Phase 2 Unknown

Uveal Melanoma, Melanoma

NCT05772624 2023-03-16

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Phase 2 Unknown

Hodgkin Disease

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05175235 2023-03-03

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

Phase 1/2 Unknown

Neoplasms

NCT03134118 2023-02-21

NIVOTHYM

Phase 2 Unknown

Thymoma

NCT03995017 2023-02-01

RiME

Phase 1/2 Unknown

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms

NCT05660993 2022-12-21

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease

NCT04612530 2022-12-20

PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer

Phase 1 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT03682276 2022-12-13

PRIME-HCC

Phase 1/2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT04913922 2022-11-08

AARON

Phase 2 Unknown

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Phase 2/3 Unknown

Prostatic Neoplasms

NCT03529890 2022-10-20

RACE IT

Phase 2 Unknown

Urinary Bladder Neoplasms

NCT05588297 2022-10-20

Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

Phase 2 Unknown

Gastrointestinal

Colorectal Cancer Liver Metastases

NCT05027204 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)

Phase 1/2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Phase 1/2 Unknown

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03542461 2022-10-03

EDEN

Phase 3 Unknown

Squamous Non-small Cell Lung Cancer

NCT04913025 2022-09-21

REFINE

Phase 2 Unknown

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT04575922 2022-09-08

Nivolumab+Ipilimumab+RT in MSS mCRC

Phase 2 Unknown

Gastrointestinal

Metastatic Microsatellite Stable Colorectal Cancer

NCT04525638 2022-08-02

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Phase 2 Unknown

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05468294 2022-07-21

Nivokin

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05265650 2022-07-19

Noelia

Phase 1/2 Unknown

Non-Small Cell Lung Cancer Metastatic

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Phase 2 Unknown

Gastrointestinal

PD-1 Antibody

NCT04013334 2022-06-16

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05213312 2022-06-15

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Phase 2/3 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05385263 2022-05-26

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Phase 2 Unknown

Lymphoma, B-Cell

NCT03374839 2022-05-06

Nivo-TIL

Phase 1/2 Unknown

Melanoma

NCT02437279 2022-04-15

OpACIN

Phase 1 Unknown

Melanoma

NCT03161756 2022-04-07

CHARLI

Phase 1/2 Unknown

Melanoma

NCT03808480 2022-04-06

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04876313 2022-04-06

NURE-Combo

Phase 2 Unknown

Muscle-Invasive Bladder Carcinoma